RNA/aTNA chimeras: RNAi effects and nucleases resistance of single and double stranded RNAs by Alagia, Adele et al.
Molecules 2014, 19, 17872-17896; doi:10.3390/molecules191117872 
 
molecules 
ISSN 1420-3049 
www.mdpi.com/journal/molecules 
Article 
RNA/aTNA Chimeras: RNAi Effects and Nucleases Resistance 
of Single and Double Stranded RNAs 
Adele Alagia 1,*, Montserrat Terrazas 1,2 and Ramon Eritja 1,* 
1 Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), CIBER-BBN Networking Centre on 
Bioengineering, Biomaterials and Nanomedicine, Jordi Girona 18–26, Barcelona 08034, Spain;  
E-Mail: montserrat.terrazas@irbbarcelona.org 
2 Institute for Research in Biomedicine (IRB Barcelona), Baldiri Reixac 10, Barcelona 08028, Spain 
* Authors to whom correspondence should be addressed; E-Mails: adele.alagia@iqac.csic.es (A.A.); 
recgma@cid.csic.es (R.E.); Tel.: +34-93-400-6100 (A.A. & R.E.);  
Fax: +34-93-204-5904 (A.A. & R.E.).  
External Editor: Derek J. McPhee 
Received: 18 August 2014; in revised form: 14 October 2014 / Accepted: 15 October 2014 /  
Published: 4 November 2014 
 
Abstract: The RNA interference pathway (RNAi) is a specific and powerful biological 
process, triggered by small non-coding RNA molecules and involved in gene expression 
regulation. In this work, we explored the possibility of increasing the biological stability of 
these RNA molecules by replacing their natural ribose ring with an acyclic L-threoninol 
backbone. In particular, this modification has been incorporated at certain positions of the 
oligonucleotide strands and its effects on the biological properties of the siRNA have been 
evaluated. In vitro cellular RNAi assays have demonstrated that the L-threoninol backbone 
is well tolerated by the RNAi machinery in both double and single-stranded fashion, with 
activities significantly higher than those evinced by the unmodified RNAs and comparable 
to the well-known phosphorothioate modification. Additionally, this modification conferred 
extremely strong resistance to serum and 3′/5′-exonucleases. In view of these results, we 
applied this modification to the knockdown of a therapeutically relevant human gene such 
as apolipoprotein B (ApoB). Further studies on the activation of the innate immune system 
showed that L-threoninol-modified RNAs are slightly less stimulatory than unmodified RNAs. 
Keywords: RNAi; siRNA; 3′-overhang chemical modification; single-stranded siRNA;  
L-threoninol; 3′-exonuclease; 5′-exonuclease; serum resistance; ApoB gene 
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1. Introduction 
In the late 1970s, it was discovered that long double-stranded oligonucleotides could efficiently 
control gene expression [1]. Thirty years later, thanks to the elucidation about the mechanism of RNAi 
pathway [2], it was demonstrated that the same effect could be produced by synthetic 21–23 nt  
double-stranded RNAs known as short interfering RNAs (siRNAs) [3]. As result of these findings, the 
post-transcriptional gene silencing disclosed its enormous therapeutic potential and its usefulness for 
studying gene function. Since the discovery of the RNAi pathway, much effort has been made in order 
to gather information on its mechanism of silencing. Once inside the cell the siRNA molecule, which 
is formed by a sense (or passenger) strand and an antisense (or guide) strand with 3′-dinucleotide 
overhangs, is incorporated into a protein complex called RNA-Induced Silencing Complex (RISC). 
Then, the loaded siRNA is unwound and only the antisense is held into the RISC, whereas the 
passenger strand is released. The antisense strand serves as a template for the recognition and cleavage 
of the target mRNA [4,5]. In theory, by virtue of their unique sequence, siRNA molecules should be 
able to discriminate between thousands of cellular mRNAs and control any disease-associated genes [6]. 
However, despite the great attractiveness of siRNAs as potential therapeutic tool, the use of these RNA 
molecules in vivo faces some key hurdles. One of the most important is their susceptibility to the 
degradation by exo- and endonucleases, which leads to short half-life in serum. Other problems are 
related to their poor ability to cross cell membranes and their rapid clearance from the bloodstream. 
Successful RNA-based therapeutics, especially in systemic applications, depends on the improvement 
of the pharmacological and the nuclease-resistant properties of siRNAs. Hence, tailored design of 
potent siRNA molecules, that ensure gene silencing at low concentration with nano/pico-molar IC50 
values and enhanced half-life, are central issues for therapeutic settings. In addition, a pivotal question 
to answer is whether the observed effects are specific and not due to unwanted “off-target” effects such 
as the activation of the immune response [7,8]. Looking back over the years, many groups have 
concentrated their efforts to address these important issues by using chemically modified siRNAs [9]. 
On the other hand, distinct approaches, like the application of single-stranded antisense siRNAs  
(ss-siRNAs), could be an attractive way to circumvent the misincorporation of the passenger strand 
into the RISC avoiding this critical off-target effect [10–13]. Recently, a new foldamer named acyclic 
Threoninol Nucleic Acid (aTNA), bearing D-threoninol (2-amino-1,3-butanediol) as building block 
tethered to one of the natural nucleobases A, C, G and T has been developed [14]. This new oligomer, 
although characterized by more flexible scaffold than the natural DNA/RNA, forms a very stable 
homoduplex in an antiparallel manner and right-handed structure. Furthermore, Murayama and  
co-workers reported that a fully modified aTNA strand cannot hybridize with the complementary 
DNA/RNA strand [15]. Thus, in view of these interesting structural properties, in this work we 
functionalized the 3′-overhangs of a siRNA molecule with two L-threoninol thymine units to explore 
its effects on the biological activities of the siRNAs. In detail, the main goal of this study is to 
investigate whether the incorporation of the L-threoninol modification in the strand termini can 
increase the resistance of the siRNAs against serum nucleases and specific exo-nucleases without 
compromising the efficacy, the potency and the duration of their silencing activity in vitro. Finally, we 
also examined the impact of this modification on the induction of the immune response. 
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2. Results and Discussion 
2.1. Synthesis of the L-Threoninol-thymine Building Block 
In order to incorporate two L-threoninol-thymine units at 3′-end of oligonucleotides via solid phase 
phosphoramidite chemistry, we prepared the succinate derivative needed for the functionalization of 
controlled pore glass (CPG) solid support (Figure 1). In parallel, with the aim of incorporating the  
L-threoninol-thymine modification at an internal position of the siRNA, the corresponding 
phosphoramidite derivative was also synthesized following previously described protocols [14,15] 
with some small modifications [16]. Reaction between thymine-1-acetic acid (1) and p-nitrophenol 
yielded an active ester [17] that reacted with the amino group of L-threoninol. Then, the  
primary hydroxyl group of the resulting L-threoninol-thymine derivative (2) was protected by a  
4,4'-dimethoxytrityl (DMT) group to give compound 3. To enable attachment to the solid support, 3 
was first reacted with succinic anhydride. The resulting succinate derivative was then linked to the free 
amino group of CPG to create the solid support 4 linked to 3. Moreover, to enable incorporation at an 
internal position, 3 was phosphitylated by the standard procedure to produce phosphoramidite 5. 
Figure 1. Schematic synthesis of the L-threoninol-thymine, the phoshoramidite and the 
functionalized solid support. 
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Reagents and conditions: (a) i: p-nitrophenol, DCC, pyridine 0 °C > RT O.N.; ii:  
L-threoninol, Et3N, DMF, RT O.N., 76%; (b) DMT-Cl, iPr2NEt, pyridine/DMF (4:2) RT 3 h, 76%; (c) i: 
succinic anhydride, DMAP, CH2Cl2, ii: LCAA-CPG, PPh3, DMAP, 2,2'-dithio-bis(5-nitropyridine), 
CH2Cl2/ACN; (d) 2-cyanoethoxy-N,N'-diisopropylaminochlorophosphine, iPr2NEt, CH2Cl2, RT, 91%. 
2.2. RNA Synthesis 
To examine whether L-threoninol-modified siRNAs can act as RNAi triggers, two L-threoninol-thymine 
monomers (TL) were incorporated at the 3′-termini of the antisense (AS2) and the sense (SS2) RNA 
strands of the siRNA targeting the Renilla luciferase mRNA (Table 1). 
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Table 1. Sequences and mass spectrometry analyses of oligonucleotides. TL: L-threoninol-
thymine monomer, TS: thymidine monomer with phosphorothioate linkage, T: thymidine. 
ON Sequence MW Calculated MW Found 
AS1 5′-UUUUUCUCCUUCUUCAGAUTT 6439 6434 
SS1 5′-AUCUGAAGAAGGAGAAAAATT 6829 (+Na) 6829 (+Na) 
AS2 5′-UUUUUCUCCUUCUUCAGAUTLTL 6497 6492 
SS2 5′-AUCUGAAGAAGGAGAAAAATLTL 6864 6859 
AS3 5′-UCCUUUCUUUCUUUCGAUATT 6439 6433 
SS3 5′-UAUCGAAAGAAAGAAAGGATT 6806 6800 
SS4 5′- ATLCUGAAGAAGGAGAAAAATT 6833 6827 
AS5 5′-UUUCUUGUUCUGAAUGUCCTT 6742 6736 
SS5 5′-GGACAUUCAGAACAAGAAATT 6518 6512 
AS6 5′-UUUCUUGUUCUGAAUGUCCTLTL 6800 6795 
SS6 5′-GGACAUUCAGAACAAGAAATLTL 6576 6570 
ASP 5′-UUUUUCUCCUUCUUCAGAUSTST -- -- 
SSP 5′- AUCUGAAGAAGGAGAAAAASTST -- -- 
In order to compare the different potency and efficacy between natural (AE1) and different 
combination of 3′-end modified (AE2, AE3, AE4) siRNAs (Table 2), unmodified antisense and sense 
strands were also prepared (AS1 and SS1) (Table 1). Moreover, we also assembled unmodified 
(APO1, unmodified sense SS5 and antisense AS5 strands) and 3′-modified (APO6, modified sense 
SS6 and antisense AS6 strands) siRNA strands targeting the endogenous gene ApoB (Tables 1 and 3). To 
ensure the specific silencing effects of the siRNAs, scrambled version of antisense and sense strands 
(AS3 and SS3, respectively) (Table 1) were designed and used as negative control (SCR) (Table 2). 
Table 2. Sequences of unmodified and modified siRNAs targeting the Renilla luciferase 
mRNA and scrambled (SCR) siRNA; Tm (±0.5 °C) and Median Inhibition Concentration 
(IC50) values (mean ± SD). TL: L-threoninol-thymine monomer; TS: thymidine monomer 
with phosphorothioate linkage; T: thymidine. 
siRNA ON Sequence Tm [°C] IC50 [pM] 
AE1 SS1 AS1 
TTAAAAAGAGGAAGAAGUCUA-5′ 
5′-UUUUUCUCCUUCUUCAGAUTT 67.8 9.8 ± 0.2 
AE2 SS1 AS2 
TTAAAAAGAGGAAGAAGUCUA-5′ 
5′-UUUUUCUCCUUCUUCAGAUTLTL N.D. 6.3 ± 0.5 
AE3 SS2 AS1 
TLTLAAAAAGAGGAAGAAGUCUA-5′ 
5′-UUUUUCUCCUUCUUCAGAUTT N.D. 14.3 ± 0.3 
AE4 SS2 AS2 
TLTLAAAAAGAGGAAGAAGUCUA-5′ 
5′-UUUUUCUCCUUCUUCAGAUTLTL 67.4 7.2 ± 0.4 
AES2 SS1 ASP 
TTAAAAAGAGGAAGAAGUCUA-5′ 
5′- UUUUUCUCCUUCUUCAGAUSTST N.D. 6.5 ± 0.2 
AES3 SSP AS1 
TSTSAAAAAGAGGAAGAAGUCUA-5′ 
5′-UUUUUCUCCUUCUUCAGAUTT N.D. 10.5 ± 0.4 
AES4 SSP ASP 
TSTSAAAAAGAGGAAGAAGUCUA-5′ 
5′-UUUUUCUCCUUCUUCAGAUSTST 67.8 8.3 ± 0.3 
SCR SS3 AS3 
TTAGGAAAGAAAGAAAGCUAU-5′ 
5′-UCCUUUCUUUCUUUCGAUATT N.D. Not active 
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Table 3. Sequences of unmodified and TL-modified siRNAs targeting the ApoB mRNA.  
TL: L-threoninol-thymine monomer, T: thymidine.  
siRNA ON Sequence 
APO1 SS5 
AS5 
TTAAAGAACAAGACUUACAGG-5′ 
5′-UUUCUUGUUCUGAAUGUCCTT 
APO6 SS6 
AS6 
TLTLAAAGAACAAGACUUACAGG-5′ 
5′-UUUCUUGUUCUGAAUGUCCTLTL 
Finally, for 5′-exonuclease studies, one L-threoninol-thymine unit was incorporated at position 2 of the 
RNA strand (SS4) (Table 1). The synthesis of RNAs bearing the modification was realized according to 
standard solid-phase synthesis protocols. 
2.3. In Vitro Evaluation of Double-Stranded and Single-Stranded Antisense siRNAs Potency 
Initially, in order to determine whether our modified siRNAs are able to suppress gene expression, 
we carried out RNAi experiments in HeLa cells with unmodified and modified Renilla luciferase  
double-stranded siRNAs (AE1, AE2, AE3, AE4, AES2, AES3 and AES4) (Table 2). Cells were  
co-transfected with two vectors carrying Renilla and Firefly luciferase genes and decreasing 
concentration of siRNAs. Twenty-four hours after transfection, luminescence was measured. 
Remarkably, all double-stranded siRNAs used in this study were potent inhibitors of Renilla activity 
with picomolar IC50 values (Figure 2A and Table 2). Very interestingly, the siRNA containing two TL 
units in the 3′-overhang of the antisense strand (AE2) displayed gene-silencing (IC50 = 6.3 pM) 
significantly higher than that of the siRNA carrying two natural thymine (AE1) (IC50 = 9.8 pM) and 
nearly comparable respect to the siRNA bearing two phosphorothioate linkages at 3′-end of the 
antisense strand (AES2) (IC50 = 6.5 pM). For the siRNA containing two TL units in the 3′-dinucleotide 
overhang of the sense strand (AE3), the gene-silencing was slightly less efficient than that observed 
for both unmodified siRNA AE1 and siRNA modified on the sense strand at 3′-end with two 
phosphorothioate linkages (AES3) (IC50 = 10.5 pM). However, despite this loss of activity, siRNA 
AE3 retained a significant inhibitory effect (IC50 = 14.3 pM). Finally, the siRNAs modified on both 
overhangs (AE4 and AES4) mainly revealed similar potency (IC50 = 7.2 pM and 8.3 pM respectively). 
Thereafter, we decided to analyze the gene-silencing capability of our modified siRNAs in a  
single-stranded fashion. Many reports [10–13] have demonstrated that single-stranded antisense 
siRNAs (ss-siRNAs) can activate the RNAi pathway. The silencing activity of ss-siRNAs, although 
less potent than that of their dsRNA counterparts, is strictly dependent on 5′-end phosphorylation. 
Thus, before transfection, ss-siRNAs (AS1; AS2; AS3) (Table 1) were 5′-phosphorylated by T4 
polynucleotide kinase (3′-phosphatase minus) (to give AS1P; AS2P; AS3P). HeLa cells were 
transfected with the 5′-phosphorylated ss-siRNAs and 24 h post-transfection luminescence was 
measured. As expected, although retaining consistent silencing ability, all the 5′-phosphorylated  
ss-siRNAs are weaker effector of RNAi, compared to the double-stranded counterparts. The 
unmodified ss-siRNA (AS1P) and the L-threoninol-modified analogue (AS2P) displayed similar 
Renilla inhibitory activity at the highest ss-siRNA concentration (100 nM) (Figure 2B). Very 
interestingly, the inhibitory activity of the modified ss-siRNA AS2P was not significantly affected by 
decreased concentration of ss-siRNA (30 nM; 10 nM; 5 nM), whereas the native ss-siRNA (AS1P) 
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exhibited weaker gene-silencing activity. Remarkably, the modified ss-siRNA (AS2P) is about 4-fold 
more potent than the native one (AS1P). HeLa cells transfected with the scrambled ss-siRNA (AS3P) 
showed luminescence levels similar to those of untreated cells. It is noteworthy to mention that at 
concentrations of 100 nM, 30 nM, 10 nM and 5 nM non-phosphorylated ss-siRNAs (AS1; AS2; AS3) 
showed no effects on Renilla expression (Supplementary Figure S7A). 
Figure 2. Luciferase assays. (A) Dose-response curves of native (AE1), TL modified 
(AE2, AE3, AE4) and PS modified (AES2, AES3, AES4) siRNAs. n = 3 ± SD; (B) Plot of 
RNAi activity of native (AS1P), 3′-end modified (AS2P) and scrambled (AS3P)  
single-stranded antisense siRNAs (ss-siRNA) 5′-phosphorylated. For experimental 
conditions see the Experimental Section. ns = p > 0.05; *** = p < 0.001. n = 3 ± SD.  
 
 
2.4. Over Time Silencing Activity Comparison of siRNAs Targeting Renilla 
Next, we performed a time course analysis of different siRNA molecules over the time of five days, 
to evaluate their long term inhibitory properties. HeLa H/P cells stably overexpressing the Luciferase 
and Renilla vectors were transfected with 20 nM of siRNAs (AE1, AE2, AE3, AE4, AES2, AES3, 
AES4 and SCR). Twenty-four hours later, cells were splitted, parallel cultures were maintained 
without any further treatments and cell pellets were collected at certain time points. Luminescence was 
assessed as described in the Experimental Section. The gene silencing activities of all the tested 
siRNAs decreased over time (Figure 3). Starting from day 3, the AE4 siRNA (containing two  
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L-threoninol units at both 3′-ends) displayed higher activity than siRNAs AE1 (native) and AES4 
(modified at both 3′-ends with two phosphorothioate linkages). Moreover, at day 5, AE4 siRNA 
preserved about 20% of RNAi activity, meaning longer-lasting effects compared to both unmodified 
AE1 and phosphorothioate-modified AES4. Of note, unlike siRNAs modified on sense strand AE3 
and AES3, siRNAs modified on antisense strand AE2 and AES2, still retained slight levels of activity 
after 5 days of incubation. 
Figure 3. Time course in HeLa H/P. n = 3 ± SD. * = p < 0.05; ** = p < 0.01;  
*** = p < 0.001.  
 
2.5. L-Threoninol Modified siRNA Silencing Depends on Ago2-Mediated Mechanism 
The Argonaute 2 protein (Ago2) is the catalytic core of the RISC complex and is responsible for 
messenger RNA cleavage activity. The perfect base-pairing between siRNA and the targeted mRNA is 
a prerequisite for Ago2-mediated cleavage [18,19]. As a consequence of the mRNA degradation the 
protein synthesis is also inhibited. In view to demonstrate that the L-threoninol modified siRNAs act 
through an Ago2-mediated mechanism, we measured the mRNA levels of the Renilla gene after the 
transfection of siRNAs into wild type Mouse Embryonic Fibroblast (MEFwt) and Mouse Embryonic 
Fibroblast knockout for Ago2 gene (MEFAgo2−/−). In detail, 1 nM and 16 pM of AE1 and AE4 siRNAs 
were transfected and 24 h later the levels of Renilla mRNA were measured. As predicted, MEFAgo2−/− 
transfected with different concentrations of AE1 and AE4, showed no significant changes in Renilla 
expression levels compared to MOCK (Supplementary Figure 8SA). In contrast, MEFwt transfected 
with AE1 and AE4 showed a dose dependent silencing of the Renilla mRNA (Supplementary  
Figure S8B). Taken together, these results indicated that the L-threoninol modification is consistent 
with gene silencing Ago2-dependent. 
2.6. Effect of L-Threoninol Modified siRNA on the HeLa Cell Survival 
The proliferation potential of HeLa cells following the transfection of unmodified AE1 and  
L-threoninol modified AE4 was tested by MTT method. 4 siRNA doses (1, 10, 50 and 100 nM) either with 
the siRNAs complexed with lipofectamine (AE1L and AE4L) either with siRNAs alone (AE1 and 
AE4) were examined. As control, untreated cells (UNT) and mock transfected cells (MOCK) were 
used. As illustrated in Supplementary Figure S9, MTT assay revealed no significant cytotoxicity due to 
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siRNA transfection in presence or in absence of transfection reagent (AE1L, AE4L, AE1 and AE4 
respectively) even at the highest dose applied (100 nM). Hence, the transfection of the native (AE1) 
and the L-threoninol modified siRNA (AE4) did not alter the normal proliferation rate of HeLa cells. 
2.7. Human Serum Nucleases Stability of Chemically Modified siRNAs 
The therapeutic application of siRNA depends not only on an efficient gene-silencing activity but 
also on satisfactory bio-stability. Prior to entering the cell and inducing gene silencing, siRNA 
molecules must face with extracellular environment such as bloodstream. SiRNAs are highly 
vulnerable to serum nucleases (endo-, 5′-exo, 3′-exonucleases and RNases), this causes short half-life 
in serum limiting their application in common therapeutic routes [20]. Chemical modification of 
siRNA overhangs is a well-accepted approach to enhance its nuclease resistance [21]. Routinely, the 
stability of siRNAs towards extracellular environment is assayed by the incubation in human blood 
serum, an excellent mimic of extracellular conditions in vivo. Thus, we evaluated the resistance of our 
modified siRNAs versus the action of nucleases by incubation in 90% human serum.  
As expected, unmodified siRNA (AE1) (Figure 4A, left panel), was completely degraded after 
about 60 min of incubation, whereas AES4 siRNA (Figure 4A, central panel) displayed higher 
resistance with complete degradation after 4 h. Remarkably, AE4 (Figure 4A, right panel) showed 
exceptional nucleases stability, with ~5% of the original siRNA remaining intact after 8 h. The plotted 
percentage of intact siRNAs over the incubation time permitted us to assess the half-life in about  
30 min for AE1, 1.3 h for AES4 and 5.4 h for AE4 (Figure 4B). Indeed, AE4 siRNA is 10-fold more 
resistant respect to AE1 and 4.5-fold more resistant than AES4. Finally, we checked the integrity of 
AE1 siRNA (Supplementary Figure 10S) to exclude degradation serum-independent. 
Figure 4. Human serum stability of unmodified and modified siRNAs (A) Nucleases stability 
of native (AE1) (left panel), double PS modified (AES4) (central panel) and double 
modified (AE4) (right panel) siRNAs; (B) Representative degradation curves (AE1 (black 
line), AE4 (red line), AES4 (blue line)) of human serum assay. Error bars indicate ± SD;  
n = 3. For statistical data analysis and experimental procedures see the Experimental Section.  
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2.8. 3′-/5′-Exonuclease Resistance Studies of Modified ssRNAs 
The degradation of siRNAs in serum is mainly due to the action of endoribonucleases belonging to 
RNAses-A family. However, a slower hydrolytic process, resulting from the attack of exonucleases, 
participates to the shortening of siRNA starting from their termini [22,23]. In order to investigate  
the effect of our modifications on these exonuclease cleavage processes, we studied the stability of 
single-stranded TL-modified RNAs against two well-studied phosphodiesterases that have catalytic 
activities similar to those of pyrophosphatases/phosphodiesterases present in serum [24]: Snake 
Venom Phosphodiesterase I (SVPD) and Bovine Spleen Phosphodiesterase II (BSP). SVPD and BSP 
hydrolyze single stranded RNAs starting from the 3′-end and the 5′-end, respectively. Interestingly, 
incubation of native (AS1) and modified (AS2) ssRNAs with SVPD revealed that the 60% of  
TL-modified ssRNA (AS2) remained intact after 72 h (Figure 5A, right panel). 
Figure 5. Stability of unmodified and modified ssRNAs against 3′- and 5′- exonucleases 
(A) SVPD degradation of native (AS1) (left panel) and 3′-end modified (AS2) (right panel) 
single stranded RNAs; (B) BSP degradation of native (SS1) (left panel) and position 2 
modified (SS4) (right panel) single stranded RNAs. For experimental conditions see 
Material and Methods.  
 
In contrast, unmodified ssRNA (AS1) was completely degraded within 1 h (Figure 5A, left panel) 
confirming that the presence of two TL at positions 20 and 21 strongly enhances the resistance to  
3′-exonuclease digestion. On the other hand, quantification of the bands proved that in the case of 
unmodified ssRNA (SS1) (Figure 5B, left panel), only the 22% of the original RNA remains intact 
after 96 h of incubation with BSP, in contrast to the 55% of SS4 (Figure 5B, right panel). Moreover, 
the degradation pattern of SS4, containing a TL unit at position 2, revealed the absence of the band 
corresponding to 20-mer degraded ssRNA (Figure 5B, right panel). This phenomenon could be 
explained by the fact that the presence of the modification at position 2 might prevent the cleavage of 
the first phosphodiester linkage. Hence, the TL modification also confers greater resistance to 
degradation of 5′-exonucleases such as BSP. 
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2.9. Keeping the Silencing: Evaluation of Long-Term RNAi Activity on ApoB Gene 
It has been reported that gene-silencing can be effective up to one month [25], the reason of 
prolonged silencing could reside either in the protective action of the RISC protein complex as well as 
in the accumulation into specific intracellular foci such as the P-bodies or in a slow cellular 
proliferation rate [8,26,27]. Thus, gene silencing mediated by siRNA is basically due to the cellular 
doubling-time and consequent serial dilution of the intracellular siRNA pool. Indeed the lengthening of 
half-life of modified siRNAs does not imply more durable silencing effects [25,28,29]. On the other 
hand, it has been reported [30], that in an intracellular environment, double-stranded siRNAs  
(ds-siRNAs) are more stable than the single-stranded siRNA (ss-siRNA) counterparts. Such different 
sensitiveness to nuclease degradation reflects, in some extent, distinct silencing activity. Hence, 
indirect evidence on the authentic stability of ss-siRNAs can be extrapolated comparing their  
gene-silencing ability. Firstly, we compared the long-lasting RNAi activity of native (APO1) and 
modified (APO6) ds-siRNAs against the endogenous ApoB gene [31]. 
To evaluate the effectiveness of our siRNAs over the time, we reverse-transfected HepG2 cells, 
which naturally express high level of the ApoB gene, [32] with 60nM of APO1 and APO6. The ApoB 
mRNA and protein levels were analyzed at certain times by RT-qPCR and western blotting. As shown 
in Figure 6A, at 24 h ApoB mRNA levels were strongly down-regulated by both unmodified (APO1) 
and modified (APO6) siRNAs. Of note, the levels of ApoB mRNA were even lower at 72 h after 
transfection, due to the extremely long half-life of ApoB mRNA, estimated of about 16 h. According to 
previous studies, underlying the correlation between prolonged silencing activity and low cell division 
rates, we noted that, in HepG2 cells which divide approximately each 48 h [33], the silencing persisted 
more than 9 days (Figure 6A). Moreover the magnitude of knockdown is not dose-dependent, 
remaining nearly the same for both APO1 and APO6. As expected, no relevant down-regulation in 
cells treated with transfection reagent only (MOCK) and control siRNA (SCR) was observed, 
denoting an absence of artifacts derived from sequence independent mechanisms. Western blot 
analyses (Figure 6B) confirmed the strong reduction of ApoB-100 protein levels, during the course of 
9 days after transfection of APO1 and APO6 siRNAs. No appreciable reduction of ApoB protein 
levels in cells treated with control siRNA (SCR) was noted. The time course analysis revealed no 
substantial difference between the performance of the native siRNA APO1 and the modified analogue 
APO6. Thus, to demonstrate that the L-threoninol-thymine modification actively contributes to more 
durable silencing effects, we reverse-transfected HepG2 cells with 60 nM of 5′-phosphorylated  
single-stranded antisense siRNAs (ss-siRNAs) (AS5P and AS6P). The ApoB mRNA and protein levels 
were quantified at certain time points by RT-qPCR and western blotting, respectively. At day 1, the 
knockdown of the ApoB mRNA reached more than 90%, but along the days, the silencing effects of  
ss-siRNAs disappeared more rapidly than the ds-siRNA counterparts (Figure 6C). Interestingly,  
at day 9 the modified ss-siRNA AS6P still preserved about 20% of ApoB knockdown, whereas the 
unmodified ss-siRNA AS5P was no longer effective (Figure 6C). Similar knockdown pattern was 
observed looking at the protein levels (Figure 6D). No appreciable silencing was found when HepG2 
cells were reverse-transfected with 60 nM of no 5′-phosphorylated ss-siRNAs (AS5 and AS6) 
(Supplementary Figure S7B). 
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Figure 6. Knockdown of the endogenous ApoB gene in HepG2 cells. (A) ApoB mRNA 
reduction with 60 nM of unmodified APO1 and modified APO6 ds-siRNAs; (B) Western 
blot and quantification plot of ApoB protein expression after siRNAs transfection. Lane 1: 
Untransfected; lane 2: Scrambled; lanes 3, 5, 7, 9: APO1 siRNAs; lanes 4, 6, 8, 10: APO6 
siRNAs; (C) APOB mRNA levels with 60 nM of 5′-phosphorylated unmodified (AS5P) 
and modified (AS6P) single-stranded siRNAs; (D) Western blot and quantification plot of 
ApoB protein levels after treatment with ss-siRNAs (60 nM). Lanes 1, 3, 5: AS5P  
ss-siRNAs; lanes 2, 4, 6: AS6P ss-siRNAs; lane 7: Mock transfection; lane 8: 
Untransfected. n = 3 ± SD. ns = p > 0.05; * = p < 0.05; *** = p < 0.001. For quantification 
of ApoB protein levels, untransfected cells were set at 100%. Error bars indicate ± SD,  
n = 2. For experimental conditions see the Experimental Section.  
 
2.10. siRNA-Mediated Innate Immune System Activation 
Despite the benefits of the induction of the interferon response in some clinical application, the 
activation of the innate immune system response by siRNA is an important aspect to avoid for the safe 
therapeutic use of them [34,35]. The human immune system has evolved to recognize exogenous  
ds-RNAs as a hallmark of viral infection, thus the intracellular presence of siRNAs could be taken for 
a dangerous signal of viral attack, inducing a potent and deleterious production of pro-inflammatory  
and antiviral cytokines (IL-18, IL-1beta, and IFN-beta) and the up-regulation of hundreds of  
interferon-stimulated genes (ISGs). Several reports have demonstrated that the stimulation of the 
immune system by siRNA molecules depends on different factors: the chemical structure and the 
length of siRNA and its specific nucleotide sequence, the relative concentration of siRNA at the time 
of transfection and the cell type involved [36–38]. The classical experimental approach for the 
evaluation of Type I interferon response, requires the monitoring of certain cytokine production  
(IFN-beta, IL-6, TNF-alpha), but its assessment can be underestimated because of the short half-lives 
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of these cytokines. An alternative approach for the evaluation of siRNA-induced immune stimulation 
consists in the screening of the mRNA levels of several Interferon Stimulated Genes (ISGs) by  
RT-qPCR [39]. It has been reported that the 2′-hydroxyl group of the uridine ribose triggers the 
immune response [40]. Based on these findings, we explored the possibility of decreasing 
immunostimulation by protecting the 3′-ends of the RNA strands with L-threoninol-thymine moieties. 
With the aim of evaluating the overall Type I interferon response caused by our siRNAs, we monitored 
some of the most notable ISGs (PKR, IFITM1, MX1, OAS1 and ISG56). As shown in Supplementary 
Figure 11SA, no significant up-regulation of the considered genes was observed, after the transfection 
of HepG2 cells with modified (APO6) and unmodified (APO1) siRNAs at different concentrations  
(40 nM; 60 nM; 100 nM), compared to untreated control cells, whereas cells treated with poly I:C  
(50 ng/mL) produced a consistent up-regulation of all genes considered. Moreover, similar results have 
been achieved by the transfection of THP-1 cells [41] with both modified (APO6) and unmodified 
(APO1) siRNA at concentration of 60 nM (Supplementary Figure 11SB). As alternative experimental 
approach to assess the activation of the Interferon response, we decided to monitor the induction of the 
pro-inflammatory cytokine IL-1beta. To this aim we used THP-1 C1 cells, [42] which are a useful tool 
to follow the production of IL-1beta [43]. In fact the presence of the fusion protein pro-IL-1beta-GLuc 
facilitates the measurement of the immune response stimulation, resulting in rapid and reliable changes 
of the luciferase luminescence. Thus, we transfected THP-1 C1 cells with both double and single 
stranded siRNAs, as it was demonstrated that double-stranded siRNAs could fail to induce a clear 
inflammatory response as their single-stranded siRNA counterparts. Oppositely to ISGs screening, 
Figure 7 illustrated a consistent over-expression of the IL-1beta respect to untransfected THP-1 C1 
cells (UNT). Poly (I:C) transfected cells were used as positive control. In detail, the induction of  
IL-1beta production was stronger in the case of unmodified ds-siRNA (APO1) respect to the modified 
one (APO6). Similar results were obtained after the transfection of ss-siRNAs, the unmodified AS5 
yielded to a higher production of IL-1beta respect to the modified one (AS6). Despite previous reports, 
the comparison of IL-1beta production siRNAs-mediated in double and single-stranded fashion are 
quite equivalent. 
Figure 7. Assessment of IL-1beta-Gluc (iGluc) production siRNA-mediated after transfection 
of unmodified (APO1 and AS5) and modified (APO6 and AS6) double and single-stranded 
siRNAs. Transfection of 50 ng/mL of Poly (I:C) was designated as Poly (I:C). n = 3 ± SD.  
* = p < 0.05; *** = p < 0.001. For experimental conditions see the Experimental Section. 
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3. Experimental Section 
3.1. Abbreviations and Acronyms 
ACN: acetonitrile, Ac: acetyl, Ac2O: acetic anhydride, AcOH: acetic acid, ApoB: apolipoprotein B; 
aTNA: acyclic threoninol nucleic acids, Bz: benzoyl, DMAP: N,N-dimethylaminopyridine, dmf: 
dimethylformamidino, DMF: N,N-dimethylformamide, DMT: dimethoxytrityl, Et3N: triethylamine,  
ES: electrospray, GAPDH: glyceraldehyde 3′-phosphate dehydrogenase, HEPES: 4-[(2-hydroxyethyl)-
1-piperazin-1-ylethane]sulfonic acid, HRMS: high resolution mass spectrometry, IFITM-1:  
interferon-induced transmembrane protein 1, ISG56: interferon-stimulated gene 56, iPr2NEt: 
ethyldisopropylamine, ISGs: interferon stimulated genes, KAcO: potassium acetate, LCAA-CPG: long 
amino alkyl controlled pore glass, LDL: low-density lipoprotein, MeOH: methanol, NMR: nuclear 
magnetic resonance, MX1: interferon induced GTP-binding protein (Myxovirus resistance), OAS-1: 
2′,5′-oligoadenylate synthetase 1, PPh3: triphenylphosphine, PKR: protein kinase R, RISC: RNA-induced 
silencing complex, RP-HPLC: reversed phase high performance liquid chromatography, RT-qPCR: 
reversed transcription quantitative polymerase chain reaction, siRNA: short interfering RNA, SCR: 
scrambled sequence, TBDMS: tert-butyldimethylsilyl, TBST: Tris buffered saline and Tween 20 solution, 
TEAA: triethylammonium acetate, THAP: 2,4,6-trihydroxyacetophenone, TL: L-threoninol-thymine 
monomer, TLC: thin-layer chromatography, Tris: 2-amino-2-hydroxymethylpropane-1,3-diol, VLDL: 
very-low-density lipoprotein. 
3.2. General Experimental Methods  
All reagents were purchased from Sigma-Aldrich (Tres cantos, Madrid, Spain) or Fluka (Sigma-Aldrich 
Química S.A., Tres cantos, Madrid, Spain) and used without further purification. Anhydrous solvents 
and deuterated solvents (CDCl3 and DMSO-d6) were obtained from Sigma-Aldrich or Fluka and used 
as supplied. All standard phosphoramidites and reagents for oligonucleotide synthesis were purchased 
from Applied Biosystem (Foster City, CA, USA) or Link Technologies (Glasgow, Scotland, UK) and 
used as received. All chemical reactions were carried out under argon atmosphere in oven-dried 
glassware. Thin-layer chromatography was carried out on aluminum-backed Silica Gel 60 F254 plates. 
Flash column chromatography was performed on silica gel SDS 0.063–0.2 mm/70–230 mesh.  
1H- 31P- and 13C-NMR spectra were recorded at 25 °C on a Varian Mercury 400 MHz spectrometer. 
Chemical shifts are reported in parts per million (ppm); J values are given in hertz (Hz). All spectra 
were internally referenced to the appropriate residual undeuterated solvent. RP-HPLC purifications 
were performed using a Nucleosil 120–10 C18 column (250 × 4 mm). UV analyses and melting curves 
were performed using a Jasco V-650 (Easton, MD, USA) instrument equipped with a thermoregulated 
cell holder. HMRS spectra were performed on a LC/MSD-TOF (Agilent Technologies, Santa Clara, 
CA, USA) mass spectrometer. MALDI-TOF spectra were recorded on a Perspective Voyager DETMRP 
mass spectrometer. The matrix used contained 2,4,6-trihydroxyacetophenone (THAP, 10 mg/mL in 
CH3CN/water 1:1) and ammonium citrate (50 mg/mL in water). 
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3.3. Synthesis of Building Blocks 
3.3.1. L-Threoninol-thymine 
(Step I): To a solution of p-nitrophenol (424 mg, 3.05 mmol) and thymine-1-acetic acid (1, 468 mg, 
2.54 mmol) in pyridine (15 mL), 1,3-dicyclohexylcarbodiimide (629 mg, 3.05 mmol) was added. The 
temperature was kept at 0 °C for 1 h and then, the mixture was allowed to react at room temperature 
overnight. The precipitate was filtered and the solvent was evaporated in vacuo. Residual pyridine was 
removed by co-evaporation with toluene followed by ACN. (Step II): The active ester was added to a 
solution of L-threoninol (295 mg, 2.8 mmol) and Et3N (780 μL, 5.6 mmol) in DMF (20 mL) and was 
stirred for 5 h at room temperature. The solution was evaporated to dryness and residual DMF was 
removed by co-evaporation with toluene followed by ACN. The residue was purified by silica gel 
chromatography and the pure product was eluted with CH2Cl2/MeOH 90:10 as a white solid (591 mg, 
78% yield). 
1H-NMR [DMSO-d6, 400 MHz] δ 11.20 (bs, 1H, CONHCO), 7.72 (d, J = 8.8 Hz, 1H, CHNHCO), 
7.39 (m, 1H, H3CC(CHNHC)), 4.58–4.55 (m, 2H, HOCH2), 4.34 (d, J = 16.4 Hz, 1H, (CO)CHAHBNCO), 
4.27 (d, J = 16.4 Hz (CO)CHAHBNCO), 3.86 (m, 1H, CH3CHOH), 3.60 (m, 1H, CH2CHNH), 3.44  
(m, 1H, OH), 1.73 (d, J = 0.8 Hz, 3H, CH3C(CO)NH, 0.98 (d, J = 6.4 Hz, 3H, CH3CHOH). HRMS 
(ES+) C11H17N3O5 calculated: 272.2803; found: [M+H]+ 272.1246. 
3.3.2. DMT-Protected L-Threoninol-thymine 
Compound 2 (167 mg, 0.61 mmol) was dried by co-evaporation with anhydrous pyridine and then 
dissolved in anhydrous pyridine (6.6 mL). Then, a solution of iPr2NEt (160 μL, 0.92 mmol) and  
4,4′-dimethoxytrityl chloride (251 mg, 0.74 mmol) in DMF (3.3 mL) was added dropwise. The 
reaction mixture was stirred for 30 min on an ice bath and then allowed to proceed at room temperature. 
After 4 h, the reaction was judged as complete by TLC (CH2Cl2/MeOH 95:5) and was quenched by 
addiction of 5% NaH2PO4 and extracted with CH2Cl2. The organic layer was dried with MgSO4, 
filtered and concentrated in vacuo. The residue that was obtained was purified by silica gel 
chromatography. The column was packed with 98:2 CH2Cl2/MeOH and the desired product was eluted 
with 95:5 CH2Cl2/MeOH. After the removal of the solvent was eliminated under reduced pressure, the 
desired pure compound (3) was obtained as a white solid (269 mg, 76% yield). 1H-NMR [CDCl3,  
400 MHz] δ 7.38–7.15 (m, 10H, DMT aromatic and CHNHCO), 7.00 (m, 1H, H3CC(CHNHC)), 6.80 
(d, J = 8.0 Hz, 4H, DMT aromatic), 4.44 (d, J = 15.6 Hz, 1H, (CO)CHAHBNCO), 4.21 (d,  
J = 15.6 Hz, 1H, (CO)CHAHBNCO), 4.08 (m,1H, CH3CHOH) 3.97 (m, 1H, CH2CHNH), 3.75 (s, 6H, 
OCH3), 3.31 (dd, J = 14.8 Hz, J = 5.2, 1H, DMTOCH2), 3.19 (dd, J = 14.8 Hz, J = 5.2, 1H, 
DMTOCH2), 1.82 (s,3H, CH3C(CO)NH), 1.08 (d, J = 6.4 Hz, 3H, CH3CHOH). 13C-NMR [CDCl3,  
75 MHz] δ 168.0, 165.4, 159.5, 152.3, 145.3, 141.8, 136.4, 136.3, 130.7, 128.7, 127.7, 113.9, 111.5, 
87.0, 68.9, 64.5, 55.5, 54.5, 53.7, 50.4, 31.1, 20.0, 12.3. HRMS (ES+) C32H35N3O7 calculated: 
574.2554; found: [M+H]+ 573.6521. 
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3.3.3. Solid Support Functionalization 
In order to conjugate compound 3 to a long-chain alkylamine-controlled pore glass support  
(LCAA-CPG), the standard methodology via hemisuccinate derivative was used. Step I): Compound 3 
(32 mg, 0.06 mmol) was dried twice by co-evaporation with anhydrous ACN under reduced pressure 
and was dissolved in anhydrous CH2Cl2 (4 mL). Succinic anhydride (12 mg, 0.13 mmol) and  
4-dimethylaminopyridine (DMAP) (16 mg, 0.13 mmol) were added. After 4 h at room temperature 
starting material was completely converted to the corresponding monosuccinate derivative (as judged 
by TLC). After treatment with 5% of NaH2PO4, the product was extracted with CH2Cl2 and the organic 
layer was dried with MgSO4, filtered and concentrated. The monosuccinate derivative was used for 
next step without any further purification. Step II): 2,2′-dithio-bis(5-nitropyridine) (9.5 mg, 0.03 mmol), 
dissolved in an CH2Cl2/ACN mixture (3:1, 150 µL) was mixed with a solution of the monosuccinate 
derivative (20 mg, 0.03 mmol) and DMAP (3.7 mg, 0.03 mmol) in ACN (500 µL). The resulting 
solution was added at room temperature to a solution of triphenylphosphine (PPh3) (8.1 mg, 0.03 mmol) in 
ACN (100 µL). The mixture was briefly vortexed and then added into a vial containing CPG (CPG Inc., 
Lincoln Park, NJ, USA) (160 mg, 0.03 mmol) and allowed to react for 3 h at room temperature. The 
functionalized support was placed onto a sintered glass funnel and washed with ACN (2 × 5 mL) and 
CH2Cl2 (2 × 5 mL) and dried under high vacuum. Finally, the derivatized support (4) was treated with 
500 μL of Ac2O/DMF 1:1 to cap free amino groups. The functionalization of the resin was determined 
by DMT quantification resulting from acid-catalyzed detritylation at 498nm using an UV-visible 
spectrophotometer (f = 25.6 µmol/g). 
3.3.4. Synthesis of the Phosphoramidite Derivative 
Compound 3 (250 mg, 0.43 mmol) was dried twice by co-evaporation with anhydrous pyridine  
under reduced pressure and was dissolved in anhydrous CH2Cl2 (5 mL). After addition of  
N,N-diisopropylethylamine (iPr2Net, 330 µL, 1.9 mmol) the reaction mixture was cooled on ice and  
2-cyanoethoxy-N,N′-diisopropylaminochlorophosphine (210 µL, 0.95 mmol) was added dropwise. 
After stirring for 1 h and 30 min at room temperature, starting material was completely converted to the 
phosphoramidite derivative as evidenced by TLC. The reaction mixture was washed with 5% NaHCO3 
and extracted with CH2Cl2. The organic layer was dried with MgSO4, filtered and evaporated to dryness. 
The residue that was obtained was purified by silica gel chromatography. The column was packed 
using 1:1 ethyl acetate/hexane + 5% triethylamine and eluted with 1:1 ethyl acetate/hexane, to give 
compound (5), as white foam (305 mg, 91% yield). 1H-NMR [CDCl3, 400 MHz] δ 7.39–7.16 (m, 10H, 
DMT aromatic and CHNHCO), 7.01 (m, 1H, H3CC(CHNHC)), 6.80 (d, J = 8.0 Hz, 4H, DMT aromatic), 
6.32 (d, 1H, J = 8.0 Hz, CH3CHOP), 4.38–4.24 (m, 3H, (CO)CHAHBNCO, (CO)CHAHBNCO, 
CH3CHOH), 4.14 (m, 1H, CH2CHNH), 3.76 (s, 6H, OCH3), 3.50–3.40 (m, 4H, OCH2CH2CN, 
CH3CHNP), 3.17–3.15 (m, 2H, DMTOCH2), 1.82 (s, 3H, CH3C(CO)NH), 1.08 (d, J = 6.4 Hz, 3H, 
CH3CHOH). 13C-NMR [CDCl3, 75 MHz] δ 167.5, 164.6, 159.4, 151.6, 145.5, 141.5, 141.4, 136.7, 136.6, 
130.8, 130.7, 128.9, 128.8, 128.5, 127.5, 118.9, 113.7, 111.6, 111.5, 86.7, 86.6, 68.8, 68.7, 62.9, 58.6, 
58.4, 55.5, 55.1, 50.7, 43.4, 43.3, 24.8, 24.7, 24.6, 24.4, 24.3, 20.5, 20.4, 19.8, 12.3. 31P-NMR [CDCl3, 
162 MHz] δ 149, 147.9. HRMS (ES+) C41H52N5O8P calculated: 773.3557; found: [M+Na]+ 796.8645. 
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3.4. RNA Synthesis 
RNA strands containing no modifications and a TL unit at position 2 were synthesized on the  
0.2 µmol scale using LV200 polystyrene supports. 3′- TL-TL-modified RNAs were synthesized on the 
1 μmol scale using CPG functionalized with TL units as solid supports. All oligonucleotides were 
synthesized on an Applied Biosystems 394 synthesizer (Foster City, CA, USA) using commercially 
available reagents and 2′-O-TBDMS-5′-O-DMT-protected phosphoramidites (ABz, Gdmf, CAc and U). 
The coupling time was 15 min and the coupling yields of natural and modified phosphoramidites were 
>97% in DMT-ON mode. Phosphorothioate oligonucleotides (ASP and SSP) (Table 1) were purchased 
from Sigma-Aldrich. SiRNAs previously described by Terrazas et al. [44] and Vaish and colleagues [45] 
were used to design siRNA duplexes against Renilla gene and ApoB gene respectively. 
3.5. Deprotection and Purification of Unmodified and Modified RNA Oligonucleotide 
Every solid support was treated at 55 °C for 1 h with 1.5 mL of NH3 solution (33%) and 0.5 mL of 
ethanol. Then, the suspension was cooled to room temperature; the supernatant was transferred into a 
clean tube and subsequently evaporated to dryness using a Speedvac concentrator. The obtained 
residue was dissolved in 1 M TBAF in THF (85 µL per 0.2 µmol resin, 330 µL per 1 µmol resin) and 
incubated for 15 h at room temperature. Finally, 1 M triethylammonium acetate (TEEA) and water 
were added to the solution (0.2 µmol synthesis: 85 µL of 1 M triethylammonium acetate (TEEA) and 
330 µL water; 1 µmol synthesis: 330 µL 1 M TEEA and 830 µL water). Oligonucleotide desalting 
procedure was conducted on NAP-5 (0.2 µmol synthesis) or NAP-10 (1 µmol synthesis) columns 
using water as eluent and evaporated to dryness. The purification of oligonucleotides was carried out 
by HPLC (DMT-ON). Column: Nucleosil 120–10 C18 column (250 × 4 mm). Solvent A: 5% ACN in 
0.1 M aqueous TEAAc (pH = 7) and solvent B: 70% ACN in 0.1 M aqueous TEAA (pH = 7). Flow 
rate: 3 mL/min. Conditions: 20 min linear gradient from 15% to 80% B and 5 min 80% B. The 
collected pure fractions were evaporated to dryness and then treated with 1 mL of 80% AcOH solution 
and incubated at room temperature for 30 min. The deprotected oligonucleotides were desalted on 
NAP-10 column using water as eluent. The resulting oligonucleotides were quantified by absorption at 
260 nm and confirmed by MALDI mass spectrometry. SiRNA duplexes were prepared by annealing 
equimolar ratios of the sense and the antisense strands in siRNA suspension buffer (100 mM KOAc, 
30 mM HEPES-KOH, 2 mM MgCl2, pH 7.4) at final concentration of 20 μM. Duplexes were heated at 
95 °C for 5 min and slowly cooled to 4 °C. 
3.6. Thermal Denaturation Studies 
Melting curves of duplex RNA were performed following change of absorbance at 260 nm versus 
temperature. Samples were heated from 20 °C to 80 °C, with a linear temperature ramp of 0.5 °C/min 
in a V-650 spectrophotometer (JASCO, Easton, MD, USA) equipped with a Peltier temperature 
control. All the measurements were repeated thrice, both the heating and cooling curves were 
measured. Buffer condition: 100 mM KOAc, 30 mM HEPES-KOH, 2 mM MgCl2, pH 7.4. 
Molecules 2014, 19 17888 
 
 
3.7. Evaluation of Stability of RNAs to Exonucleases 
3′-Exonuclease. Unmodified (AS1) and 3′-end modified (AS2) ssRNA (120 pmol) were incubated 
with Phosphodiesterase I (SVPD) from Crotalus adamanteus venom (EC 3.1.4.1) at 37 °C, as 
previously described [44]. Briefly, at established times, aliquots of the reaction mixtures (5 µL) were 
added to a solution of 9 M urea (15 µL) and immediately frozen at −80 °C. Samples were run on a 
denaturing 20% polyacrylamide TBE gel containing urea (7 M) and visualized by Sybr Green I staining. 
5′-Exonuclease. Unmodified (SS1) and position 2 modified (SS4) ssRNAs (300 pmol) were 
incubated with Bovine Spleen Phosphodiesterase II (BSP) (EC 3.1.16.1) (0.37 U), in a solution 
containing NaOAc 100 mM (pH6.5) at 37 °C (total volume 50 µL). At certain times, aliquots of the 
reaction mixtures (5 µL) were added to a solution of 9 M urea (15 µL) and immediately frozen at  
−80 °C. Samples were run on a denaturing 20% polyacrylamide TBE gel containing urea (7 M) and 
visualized by Sybr Green I staining (Sigma Aldrich). 
3.8. Serum Nucleases Stability Assay 
Ds-RNAs containing no modifications, two TL units and two phosphorothioate linkages at both  
3′-ends (AE1, AE4 and AES4 respectively; 150 pmol) were incubated with 90% human serum at  
37 °C. At appropriated times, aliquots of the reaction mixtures were separated, added to a glycerol 
loading solution and immediately frozen at −80 °C. Then, all samples were run on a non-denaturing 
20% polyacrylamide TBE gel and visualized by Sybr green I staining. As dsRNA ladder, siRNA 
marker (New England Biolabs, Ipswich, MA, USA) was used. 
3.9. Cells 
HeLa cells (ATCC), HepG2 cells (ATCC), MEFwt cells (ATCC) and MEFAgo2−/− cell lines (a gift of 
Dr. O’Carroll [46]) were maintained in monolayer culture at exponential growth in high-glucose Dulbecco 
modified Eagle medium (DMEM) (Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 
10% heat inactivated fetal bovine serum (Gibco, Life Technologies) and 1x penicillin/streptomycin 
solution (Gibco, Life Technologies), HeLa H/P cells stably expressing pGL4.14 [luc2/Hygro] 
(Promega) and pRL-tk-Puro (a kind gift of Dr. Waaler [47]) were maintained under hygromycin B 
(200 µg/mL) and puromycin (2 µg/mL) selection pressure. Human THP-1 monocyte cell line, a kind 
gift of Dr. Noé (University of Barcelona, Spain) and THP-1 iGLuc C1 cell line stably transduced with 
iGLuc reporter (pro-IL-1beta-GLuc-Flag) (kindly provided by Dr. Hornung [42]) were maintained in 
suspension culture at exponential growth with HAM F12 medium (Gibco, Life Technologies) 
supplemented with 10% heat inactivated fetal bovine serum and 1× penicillin/streptomycin solution. 
All cell lines were incubated at 37 °C in humidified environment with 5% CO2 and periodically 
checked for the presence of mycoplasma contamination. Cell viability was monitored by Trypan Blue 
exclusion assay and was higher than 95% in all experiments. 
3.10. Luciferase Assay 
For the luciferase assay, HeLa cells were plated in 24-well tissue culture plates at density of 1 × 105 
cells per well 24 h before transfection. Co-transfection of reported plasmids and different siRNAs 
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molecules was performed using Lipofectamine 2000 (Life Technologies) in accordance with 
manufacturer’s instructions. Specifically, combinations of 1 µg of pGL3 (Promega, Madrid, Spain), 
containing the Photinus pyralis luciferase gene; 0.1 µg of pRL-TK (Promega), containing the Renilla 
reniformis luciferase gene and siRNAs at different concentrations siRNAs (1 nM, 0.3 nM, 0.16 nM,  
60 pM, 16 pM, 8 pM, and 2 pM) were co-transfected. The siRNAs are designed to target the Renilla 
gene (accession number: M63501) in the 510–528 bp range. The inhibitory effects of siRNAs on 
Renilla protein expression was determined on lysates collected 24 h after transfection using the  
Dual-Luciferase Reporter Assay System (Promega) and a SpectraMax M5 luminometer (Molecular 
Devices, Sunnyvale, CA, USA). The ratios of Renilla luciferase (hRluc) to Photinus luciferase (luc+) 
protein activities were normalized to mock transfection, as control, and the mock activity was set as 
100%. The results are representative of at least three independent experiments and each transfection 
was performed in triplicate. IC50 values were calculated by using GraphPad Prism software with the 
sigmoidal dose-response function. 
3.11. Ago2-Mediated Silencing Assay 
MEFwt and MEFAgo2−/− cells were plated in 24-well tissue culture plates at a density of  
0.8 × 105 cells per well 24 h before transfection. Co-transfection of reported plasmids (1 µg of pGL3 
and 0.1 µg of pRL-TK) and different siRNAs molecules (AE1 and AE4) at concentration of 1 nM and 
16 pM was performed with lipofectamine LTX (Life Technologies) in accordance with manufacturer’s 
protocol for MEF. After 24 h, the samples were harvested for RNA extraction. 
3.12. MTT Assay 
The MTT assay is based on the protocol previously described [48]. Briefly, HeLa cells were seeded 
at density of 6 × 103 per well into 96-well plate. After 24 h, naked siRNAs (AE1, AE4 and AES4) and 
siRNAs complexed with lipofectamine 2000 (AE1L, AE4L and AES4L) were added to cells at 
different concentrations (1 nM, 10 nM, 50 nM, 100 nM). The culture medium after 24 h of incubation 
was changed and cells were incubated for 4 h with 0.8 mg/mL of MTT reagent. Finally, after washing 
with PBS, 200 µL of DMSO were added, gentle shaking for 15 min permitted the complete dissolution 
of formazan crystals. Absorbance was recorded at λ = 570 nm using the microplate spectrophotometer 
system SpectraMax M5 (Molecular Devices). Results were analyzed with GraphPad Prism software 
and are presented as percentage of the control values. 
3.13. THP-1 Interferon Assay 
THP-1 cells were seeded into 24-well tissue culture plates at density of 2 × 105 cells per well in 
culture medium without antibiotics. SiRNAs were diluted to the desired concentration (60 nM) in 
OptiMem serum free medium (Gibco, Life Technologies) and transfections were performed using 
Interferin (Poly Plus Transfection, Inc., New York, NY, USA) in accordance with manufacturer’s 
instructions. After 24 h, the samples were collected for subsequent RNA extraction. As positive control 
we used cells transfected with Poly (I:C) (50 ng/mL, Sigma-Aldrich), this dsRNA analogue is 
sufficient to activate both the inflammasome pathway and the Type I IFNs response [49]. 
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3.14. Single-Stranded Antisense siRNA 5′-End Phosphorylation 
Before transfection, 300 pmol of single stranded antisense siRNA (AS1; AS2; AS3; AS5; AS6)  
(ss-siRNA) were incubated for 90 min at 37 °C with 100 mM of ATP and T4 Polynucleotide kinase 
(3′-phosphatase minus) (New England Biolabs, Ipswich, MA, USA), then for 30 min at 65 °C to 
inactivate the enzyme, following the manufacturer’s instructions. 
3.15. HepG2 Transfection 
HepG2 cells were reverse-transfected in gelatin coated 6-well plates at density of 0.6 × 106 cells per 
well with 60 nM of double-stranded or single-stranded antisense siRNA, targeting endogenous ApoB 
mRNA using Lipofectamine RNAiMAX Reagent (Life Technologies) and following the manufacturer’s 
instructions for HepG2 cells. For time course experiments, 24 h after transfection, cells were splitted 
and parallel cultures were maintained for 9 days without any further treatments. For interferon assays, 
cells were reverse-transfected as above with different concentrations of siRNAs (20, 60, 100 nM) and 
pellets were harvested after 24 h. 
3.16. THP-1 iGluc C1 
THP-1 iGluc C1 cells were seeded in 96-well plates (0.2 × 106 cells per well) 4 h before 
transfection to permit cell attachment. Then, the cells were transfected with 20 nM of either  
double-stranded siRNAs (APO1 and APO6) or single-stranded siRNAs (AS5 and AS6) using 
Interferin reagent (Polyplus Transfection), following the manufacturer’s instructions for THP-1 cells. 
After 22 h the supernatants were collected and to measure the luminescence levels, equal volumes of 
supernatants and coelenterazine (4.4 µM, Life Technologies) were mixed, as previously described [43]. 
As positive control, cells were transfected with Poly (I:C) (50 ng/mL). 
3.17. Isolation of RNA and RT-qPCR 
According to the manufacturer’s protocols, total RNA was isolated from HepG2 and THP-1 cells 
using Gene Jet RNA (Thermo Fischer Scientific, Waltham, MA, USA) and from MEFwt and 
MEFAgo2−/− with TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Then, extracted RNA was 
quantified by NanoDrop (Thermo Scientific). Of each RNA sample, 5 µg was treated with DNase I 
[DNase I (RNase free) New England Biolabs] following manufacturer’s instruction. Then, the reverse 
transcription reaction, 1 µg of total RNA, was carried out with random hexamer primers and Revertaid 
H minus RT enzyme (Thermo Scientific) according to the manufacturer’s instructions. First strand 
cDNA was subsequently diluted 4 times in nuclease-free water before addition of 1 µL of resulting 
cDNA to the real-time mixture. Real-time PCR was accomplished in a total volume of 20 µL, using 
Maxima SYBR Green protocol (Thermo Scientific) following to the manufacturer’s instructions. The 
reference gene GADPH was used as internal control. Renilla and ApoB silencing was calculated and 
represented as 2−∆∆Ct method, where 2−∆∆Ct = [(Ct gene of interest − Ct internal control) sample A − (Ct 
gene of interest − Ct internal control) sample B)]. ISGs induction was measured and represented as 
2−∆Ct method, where 2−∆Ct = [(Ct gene of interest − Ct internal control)]. All primers listed in Table S1 
were purchased from Sigma-Aldrich and Primer-Blast was used as primer designing tool [50]. 
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Furthermore, to verify the specificity and the identity of the PCR products and to exclude the formation of 
primer-dimers, for each pair of primers, melting curve analyses were performed. As negative control, 
No-template controls (NTCs) were included. Thermal cycling conditions: 95 °C for 10 min, followed 
by 50 cycles of 95 °C for 15 s, 60 °C for 30 s, and 72 °C for 30 s, and concluded at 72 °C for 10 min. 
3.18. Western Blot Analysis 
Cells treated with ApoB siRNAs were harvested at certain times, washed in PBS and lysed with  
100 µL of lysis buffer (50 mM Tris-HCl pH8, 150 mM NaCl, 1% (v/v) NP-40, 0.1% (v/v) SDS, 0.25% 
(v/v) DOC) at 4 °C for 1 h. Protein concentrations were determined using the Bio-Rad protein assay 
system (Bio-Rad laboratories, Madrid, Spain). Aliquots of cell extracts, containing 20 µg of proteins, 
were denatured at 95 °C for 5 min in Laemmli buffer and resolved by 5% SDS-Page, and then blotted 
on a poly(vinylidene difluoride) membrane (Immobilion-P, Millipore, Milford, MA, USA). 
Membranes were blocked for 1 h in 1× TBST buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.20% 
(v/v) Tween-20) containing 5% (w/v) skim milk and subsequently incubated with the mouse anti-APOB 
antibody (ab63960, Abcam, Cambridge, UK) at 4 °C overnight at dilution 1:2000 in blocking buffer. 
The loading control β-actin was detected by mouse anti-Beta-actin antibody (Sigma-Aldrich) and 
diluted in blocking buffer 1:3500. Blots were washed 3 times with 1× TBST buffer and then incubated 
with the HRP-conjugated secondary antibody (anti-mouse IgG, W2041, Promega) for 1 h at room 
temperature. After 3 times washing with 1× TBST buffer, blots were incubated with ECL Western 
Blotting Substrate (Pierce, Rockford, IL, USA). Chemiluminescence was quantified as the ratios of 
ApoB to Beta-actin signal intensities and values obtained from siRNA-treated HepG2 cells were 
normalized to those obtained from HepG2 cells incubated in absence of siRNA. 
3.19. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software (GraphPad, San Diego, CA, 
USA). Unless otherwise noted, datasets were analyzed for statistical significance by one-way ANOVA 
and two-way ANOVA to generate P-values. IC50 determination was performed using non-linear 
regression analysis (log [inhibitor] vs. normalized response). Finally, human serum half-lives were 
determined using two phase decay equation. Quantifications of western blots and degradation assays 
were accomplished using ImageJ 1.46 software (NIH, Bethesda, MD, USA). For 3′-exonuclease,  
5′-exonuclease and human serum nucleases stability experiments, intact bands percentage values were 
measured as the ratios of time specific band to time zero band intensities. 
4. Conclusions 
In this study we have analyzed the effect of the presence of an acyclic DNA mimetic at the 3′-ends 
of siRNAs. As the 3′-overhangs positions are not base paired, thermal stability of duplex siRNAs is not 
affected by this modification (Table 2). The different IC50 values emerged from the dual luciferase 
experiments reveal that all siRNAs used in our studies (AE1, AE2, AE3, AE4, AES2, AES3, and 
AES4) are active and potent inhibitors of Renilla luciferase expression. Even though the AE2 and AE4 
siRNAs retain stronger activity compared to native siRNA (AE1), were found to be as effective as the 
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AES2 and AES4 (Figure 2A). But at longer time the AE4 siRNA retained more persistence silence 
capability compared to the AES4 (Figure 3). Typically, siRNAs carrying modifications on the 
antisense 3′-overhang show silencing activity comparable to or lower than that of siRNAs [44,51–55] 
and only a few reports have described an improved silencing activity [56]. Interestingly, the siRNA 
modified on the antisense strand (AE2) demonstrates a better activity than the siRNA modified on 
sense strand (AE3). The higher silencing activity of AE2 and AES2 could be due to a better 
recognition of the 2 TL-modified and 2 PS-modified on 3′-overhang by the PAZ domain of the Ago2 
protein [51,55,57,58]. Then, the stronger potency of the modified ss-siRNA AS2P respect to the AS1P 
underlines the real involvement of the L-threoninol-thymine modification to greater RNAi activity and 
also confirms the compatibility of the modification with the RNAi machinery (Figure 2B). Furthermore, 
data gathered from MEFwt and MEFAgo2−/− knockdown experiments, corroborate the thesis that gene 
silencing induced by L-threoninol modified siRNA (AE4) depends, as the native siRNA (AE1), 
through Ago2-mediated mechanism (Supplementary Figure S8). Finally, the absence of cytotoxicity of 
the L-threoninol modification evaluated by the MTT assay (Supplementary Figure S9), excludes that 
the silencing siRNA-mediated is due to unspecific effects such as the protein synthesis inhibition and 
makes this modification appropriate for in vivo and in vitro applications. The good levels of RNAi 
activity displayed by our TL-modified siRNAs prompted us to analyze the specific contribution of the 
TL modification on protection against exo/endo-nucleases. Nuclease resistance is a main issue during the 
delivery of naked siRNAs, unsatisfactory serum stability implies impracticability of systemic therapeutic 
strategies. The human serum experiment restates the extremely short half-life of native siRNAs (AE1), 
and proves the considerable superior resistance conferred by the 2 TL units at both 3′-ends (AE4) even 
against the RNA protected at both 3′-ends with two phosphorothioate linkages (AES4) (Figure 4B). 
Thereafter analyses of the 3′- and 5′-exo degradation pattern revealed a significant increase in stability to 
specific phosphodiesterases such as Snake venom phosphodiesterase I and Bovine spleen 
phosphodiesterase II. Moreover, the analysis of double (APO1 and APO6) and single-stranded (AS5 
and AS6) siRNAs targeting the endogenous APOB gene provides an exhaustive overview on the TL 
modification compatibility with the endogenous RNAi machinery and also proves the longer silencing 
duration achieved by the presence of the modification especially in ss-siRNAs fashion. Finally,  
the L-threoninol modified siRNAs (APO6 and AS6) are less prone to activate the IL-1beta production 
than the unmodified siRNAs (APO1 and AS5), thus the replacement of natural thymidine with  
L-threoninol-thymine monomer can attenuate the activation of the immune response. In conclusion, 
evidence on the long-lasting silencing, the enhanced nucleases resistance, the absence of cytotoxicity, 
the silencing Ago2-mediated and less immunogenicity of the L-threoninol modified siRNA, suggests that 
this modification is a good candidate for further investigations involving in vivo and structural studies. 
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